The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod

Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?

(2015) Pan Pantziarka et al.   Future Oncology

Cellular and metabolic functions for autophagy in cancer cells

(2015) Candia M. Kenific et al.   TRENDS IN CELL BIOLOGY

FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling

(2014) Zhaoyang Lu et al.   BMC CANCER

Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro

(2014) Giulia Marvaso et al.   CANCER BIOLOGY & THERAPY

SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell

(2014) Hao Liu et al.   CELLULAR SIGNALLING

FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1

(2014) Ying Xing et al.   Journal of Digestive Diseases

Cancer-related inflammation and treatment effectiveness

(2014) Connie I Diakos et al.   LANCET ONCOLOGY

Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

(2014) R Pippa et al.   LEUKEMIA

Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia

(2014) R Mani et al.   LEUKEMIA

14-3-3 Proteins Play a Role in the Cell Cycle by Shielding Cdt2 from Ubiquitin-Mediated Degradation

(2014) A. Dar et al.   MOLECULAR AND CELLULAR BIOLOGY

PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential

(2014) I. Cristobal et al.   MOLECULAR CANCER THERAPEUTICS

FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway

(2014) Li Zhang et al.   TUMOR BIOLOGY

FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors

(2013) Miki Kiyota et al.   APOPTOSIS

Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells

(2013) Bo Yu et al.   BIOMATERIALS

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

(2013) J. J. Oaks et al.   BLOOD

miRNA-95 Mediates Radioresistance in Tumors by Targeting the Sphingolipid Phosphatase SGPP1

(2013) X. Huang et al.   CANCER RESEARCH

Small Rho GTPases in the control of cell shape and mobility

(2013) Arun Murali et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells

(2013) David G. Watson et al.   CELLULAR SIGNALLING

Molecular Pathways: Reactive Oxygen Species Homeostasis in Cancer Cells and Implications for Cancer Therapy

(2013) V. Nogueira et al.   CLINICAL CANCER RESEARCH

FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system

(2013) FV Pereira et al.   Clinics

Sphingosine-1-phosphate receptor 2

(2013) Mohamad Adada et al.   FEBS Journal

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration

(2013) Michael J Kluk et al.   LABORATORY INVESTIGATION

A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery

(2013) Yicheng Mao et al.   Nanomedicine-Nanotechnology Biology and Medicine

FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway

(2013) Mei-Hong Li et al.   PEDIATRIC BLOOD & CANCER

PP2A-Mediated Anticancer Therapy

(2013) Weibo Chen et al.   Gastroenterology Research and Practice

Design, Synthesis, and Antileukemic Activity of Stereochemically Defined Constrained Analogues of FTY720 (Gilenya)

(2013) Rebecca Fransson et al.   ACS Medicinal Chemistry Letters

PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis

(2013) X Cheng et al.   Blood Cancer Journal

Effect of alkyl chain length on sphingosine kinase 2 selectivity

(2012) Kenneth Knott et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma

(2012) Y. Liu et al.   BLOOD

Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice

(2012) K. B. Lorvik et al.   BLOOD

The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism

(2012) Francesca Tonelli et al.   BRITISH JOURNAL OF PHARMACOLOGY

Sphingosine-1-Phosphate Links Persistent STAT3 Activation, Chronic Intestinal Inflammation, and Development of Colitis-Associated Cancer

(2012) Jie Liang et al.   CANCER CELL

Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways

(2012) Gernot Walter et al.   CELL CYCLE

Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models

(2012) R. Rosa et al.   CLINICAL CANCER RESEARCH

Molecular Targets of FTY720 (Fingolimod)

(2012) M.R. Pitman et al.   CURRENT MOLECULAR MEDICINE

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

(2012) Sahar A. Saddoughi et al.   EMBO Molecular Medicine

Autophagy induced by FTY720 promotes apoptosis in U266 cells

(2012) Aijun Liao et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: Functional differences between sphingosine kinase 1a and 1b

(2012) Keng Gat Lim et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

A fluorescent assay for ceramide synthase activity

(2012) Hyun Joon Kim et al.   JOURNAL OF LIPID RESEARCH

Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma

(2012) A. Estrada-Bernal et al.   NEURO-ONCOLOGY

FTY720 Suppresses Liver Tumor Metastasis by Reducing the Population of Circulating Endothelial Progenitor Cells

(2012) Chang Xian Li et al.   PLoS One

Melanoma Occurring During Treatment With Fingolimod for Multiple Sclerosis: A Case Report

(2011) Katrin Baumann Conzett   ARCHIVES OF DERMATOLOGY

FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells

(2011) Craig T. Wallington-Beddoe et al.   Autophagy

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins

(2011) Kimberly Romero Rosales et al.   BIOCHEMICAL JOURNAL

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

(2011) L. Alinari et al.   BLOOD

Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia

(2011) A. Liao et al.   BLOOD

Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model

(2011) Yoanne Mousseau et al.   BREAST CANCER RESEARCH AND TREATMENT

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers -- Letter

(2011) A. G. Dumont et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

(R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells

(2011) Keng Gat Lim et al.   CELLULAR SIGNALLING

Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy

(2011) Jens Ingwersen et al.   CLINICAL IMMUNOLOGY

Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma

(2011) Hany A. Omar et al.   HEPATOLOGY

FTY720 Analogues as Sphingosine Kinase 1 Inhibitors

(2011) Keng G. Lim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Reactivating PP2A by FTY720 as a Novel therapy for AML with C-KIT tyrosine kinase domain mutation

(2011) Yan Yang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Fingolimod (FTY720): A Recently Approved Multiple Sclerosis Drug Based on a Fungal Secondary Metabolite

(2011) Cherilyn R. Strader et al.   JOURNAL OF NATURAL PRODUCTS

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

(2011) I Cristóbal et al.   LEUKEMIA

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

(2011) M. Mehling et al.   NEUROLOGY

Enhancement of Neoangiogenesis and Follicle Survival by Sphingosine-1-Phosphate in Human Ovarian Tissue Xenotransplants

(2011) Reza Soleimani et al.   PLoS One

FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: A protective role of autophagy

(2010) Ning Zhang et al.   Autophagy

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers

(2010) K. G. Roberts et al.   CANCER RESEARCH

FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1

(2010) D. Pchejetski et al.   CANCER RESEARCH

Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function

(2010) Joanna M. Woodcock et al.   CELLULAR SIGNALLING

FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells

(2010) Francesca Tonelli et al.   CELLULAR SIGNALLING

FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

(2010) Q. Liu et al.   CLINICAL CANCER RESEARCH

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance

(2010) Suriyan Ponnusamy et al.   Future Oncology

Improved Intratumoral Oxygenation Through Vascular Normalization Increases Glioma Sensitivity to Ionizing Radiation

(2010) Mackenzie C. McGee et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma

(2010) Guichun Huang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice

(2010) Tongsen Zheng et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

(2010) Volker Brinkmann et al.   NATURE REVIEWS DRUG DISCOVERY

Suppression of Androgen-Independent Prostate Cancer Cell Aggressiveness by FTY720: Validating Runx2 as a Potential Antimetastatic Drug Screening Platform

(2009) C.-W. Chua et al.   CLINICAL CANCER RESEARCH

Ceramide Synthesis Is Modulated by the Sphingosine Analog FTY720 via a Mixture of Uncompetitive and Noncompetitive Inhibition in an Acyl-CoA Chain Length-de pend ent Manner

(2009) Sujoy Lahiri et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Suppression of Hepatocellular Carcinoma Recurrence After Rat Liver Transplantation by FTY720, a Sphingosine-1-Phosphate Analog

(2009) Yuichiro Ushitora et al.   TRANSPLANTATION

Effects of Phosphorylation of Immunomodulatory Agent FTY720 (Fingolimod) on Antiproliferative Activity against Breast and Colon Cancer Cells

(2008) Yasuo Nagaoka et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes

(2008) M. V. Shah et al.   BLOOD

FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C   Signaling

(2008) J.-H. Hung et al.   CANCER RESEARCH

Antiproliferative and Overadditive Effects of Rapamycin and FTY720 in Pancreatic Cancer Cells In Vitro

(2008) Y. Shen et al.   TRANSPLANTATION PROCEEDINGS